MAM
CBMG

Martingale Asset Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Martingale Asset Management’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-38,707
Closed -$711K – 1097
2020
Q3 		$711K Sell
38,707
-48,200
-55% -$810K 0.01% 721
2020
Q2 		$1.3M Buy
+86,907
New +$1.24M 0.02% 668

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Martingale Asset Management's CBMG Position: Q4 2020 in Review

Martingale Asset Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 38,707 shares — an estimated $711K sold.

Martingale Asset Management first reported a position in CBMG in Q2 2020 and held it in 2 quarters. The position peaked at $1.3M in Q2 2020. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

  • Martingale Asset Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
  • Martingale Asset Management sold 38,707 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $711K.
  • Martingale Asset Management first reported a position in Cellular Biomedicine Group, Inc. in Q2 2020 and held it in 2 quarters.
  • Martingale Asset Management's Cellular Biomedicine Group, Inc. position peaked at $1.3M in Q2 2020.
  • 67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on Martingale Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.